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Ever since a pivotal study in 1997 demonstrated superiority of gemcitabine over 5-FU, gemcitabine
monotherapy has, until recently, comprised the standard of care in patients with advanced pancreatic
cancer. However, the emerging recognition of the pancreatic cancer microenvironment, including the
particularly abundant stroma, as playing a key role in disease progression and resistance to chemother-
apy has marked somewhat of a paradigm shift in the way treatment of advanced pancreatic cancer is
viewed, with these very same biological defenses conversely offering an Achilles heel with which to com-
bat this aggressive disease. Recently, this approach was validated for the ﬁrst time in a pivotal phase III
trial in which patients received nab-paclitaxel, a stroma-targeted drug, with gemcitabine. Overall sur-
vival was signiﬁcantly (p < 0.001) prolonged in the combination arm, compared with gemcitabine alone,
and thus these convincing results pave the way forward for future treatment regimens that employ a
multipronged approach, targeting not only the primary tumor but the surrounding microenvironment
as well.
 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Of all the solid tumors, pancreatic cancer carries one of the most
dismal prognoses, with a median overall survival duration of
approximately 6 months following diagnosis and an overall sur-
vival rate at 5 years of less than 5% [1]. Reasons for this include
marked tumor resistance to chemotherapy and radiotherapy, lack
of speciﬁc early symptoms resulting in advanced disease upon
diagnosis and the ability of pancreatic cancer cells to metastasize
early in disease development [2]. Indeed, for the approximately
15–20% of patients with seemingly operable disease at presenta-
tion, micrometastases have usually already been established [3]
and 85% of these patients will eventually experience relapse and
subsequent cancer-related death [4]. However, the majority of
patients are diagnosed at a late stage in disease development, with
approximately 30% and 50% having locally-advanced unresectable
and metastatic disease, respectively, upon presentation [5].
Currently, deﬁnitive risk factors for pancreatic cancer remain
largely unknown. Of several environmental agents possibly associ-
ated with increased risk, only tobacco use has been established as
having a causative role, with smokers experiencing a 2.5–3.6-fold
higher risk of disease [1]. Other possible environmental causesare nitrites which are used as preservatives in processed meats
[6]. Overweight or obesity was conﬁrmed as a risk factor in a large
case-control study in which it was shown that subjects who were
overweight from 14 to 39 years of age or who were obese from 20
to 49 years of age had a statistically signiﬁcant increased risk of
pancreatic cancer (highest odds ratios of 1.67 [95%CI: 1.20–2.34]
and 2.58 [95%CI: 1.70–3.90], respectively), regardless of whether
or not they had concomitant diabetes mellitus, another possible
risk factor. Additionally, overweight or obesity resulted in earlier
onset of disease [7].
Diabetes is associated with pancreatic cancer but whether or
not it is a causative factor, an effect due to pancreatic cancer or
both has yet to deﬁnitively determined. In a population-based
cohort study conducted in Taiwanese patients, diabetes mellitus
for less than 2 years was found to be signiﬁcantly correlated with
increased risk of pancreatic cancer, with the incidence being
approximately 4 times higher than that observed in non-diabetic
patients (27.81 vs. 6.96 cases per 10,000 patient-years). However,
an increased risk of pancreatic cancer was not found in patients
with long-term diabetes [8].
Familial mutations are important risk factors for pancreatic can-
cer, with 7–10% of pancreatic cancer patients having a family his-
tory of this disease. A ﬁrst-degree relative of an individual with
familial pancreatic cancer has a 9-fold higher risk of developing
this neoplasm and those with 3 or more affected ﬁrst-degree
relatives have a 32-fold higher risk. Moreover, familial pancreatic
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lesions and extra-pancreatic malignancies.
Other possible risk factors that have yet to be validated include
a high-fat diet or a diet that contains few vegetables, non ‘O’ blood
type, African-American ethnicity, older age and male gender [9].
Treatment for early-stage pancreatic cancer comprises surgery
followed by adjuvant chemotherapy which is usually gemcitabine
or 5-FU (ﬂuorouracil) [10]. Recently, a long-term analysis was pub-
lished of the pivotal CONKO-001 study which compared adjuvant
gemcitabine with observation alone in patients with resected pan-
creatic cancer. After a median follow-up period of 11.3 years, dis-
ease-free survival, the primary endpoint, was signiﬁcantly longer
in the gemcitabine arm (median of 13.4 vs. 6.7 months;
p < 0.001) as was survival (median of 22.8 months vs. 20.2 months;
p = 0.01). Moreover, the 5-year overall survival of 20.7% vs. 10.4%
and 10-year overall survival of 12.2% vs. 7.7% was prolonged [11].
With respect to administration of neoadjuvant therapy, results
so far have been inconclusive in patients with primarily resectable
disease [10]. In patients with borderline resectable/unresectable
pancreatic cancer, administration of chemotherapy may increase
the chance of resection and, consequently, improve survival out-
comes [12]. Regarding the value of radiotherapy in the treatment
of locally advanced pancreatic cancer, addition of radiotherapy is
not superior to continuing chemotherapy after four months of
induction therapy, with the ﬁnal results of the international phase
III LAP 07 study showing no signiﬁcant differences in efﬁcacy
between chemotherapy and chemoradiotherapy arms [13].
Unfortunately, due to the majority of patients presenting with
disease that is already unresectable and/or metastatic, treatment
is usually palliative, with the main goals being to ameliorate symp-
toms and extend survival.
Ever since gemcitabine was conﬁrmed as the standard of care
for advanced pancreatic cancer in 1997 [14], progress in improving
survival outcomes has been painfully slow, with many different
gemcitabine-based combinations demonstrating no more efﬁcacy
than gemcitabine alone, aside from when administered in patients
with good performance status [15].
Regarding predictive biomarkers for pancreatic cancer treat-
ment, human equilibrative nucleoside transporter 1 (hENT-1) has
been identiﬁed as a predictor of response to gemcitabine. A multi-
variate analysis of the ESPAC-1 and -3 trials showed that increased
intratumoral hENT-1 was signiﬁcantly correlated to response to
gemcitabine (p = 0.008) but not ﬂuorouracil [16]. Similar outcomes
were seen in another multivariate analysis of the RTOG 9704 trial,
in which higher hENT-1 levels in gemcitabine recipients were
associated with signiﬁcantly (p = 0.018) longer overall survival,
compared with those patients with lower hENT-1 levels
(median of 24.2 vs. 14.8 months) [17]. Presently, a phase II trial
(NCT01726582) is being conducted in patients with borderline
resectable/unresectable pancreatic cancer which is assessing 6
biomarkers considered to be predictive of treatment response-
secreted protein acidic and rich in cysteine (SPARC; nab-paclit-
axel), ribonucleotide reductase M1 (RRM1; gemcitabine), excision
repair cross-complementation group 1 (ERCC1; platinum analogs),
topoisomerase 1 (TOPO1; irinotecan), hENT-1 (gemcitabine) and
TYMS (ﬂuorouracil) [18].Genetics
Over the last decade our understanding of pancreatic cancer
genetics has increased substantially, with a number of germline
and somatic mutations being identiﬁed and mapped. KRAS-activat-
ing mutations, a somatic mutation found in approximately 90% of
pancreatic cancers, and its downstream signaling pathways MAPK
and PI3K have been the focus of intense efforts to develop targetedtherapies [19]. Unfortunately, success so far has been thwarted due
to the difﬁculty in developing a protein that precisely matches the
active site in the KRAS protein. As KRAS only becomes fully acti-
vated once it is transported and embedded in the cell membrane,
a new approach has been taken in which KRAS itself is not targeted
but instead the target is its transport protein PDE-d. Preclinical
results appear promising thus far but have yet to be validated in
clinical trials [20].
Other common somatic mutations in pancreatic cancer include
inactivation of tumor suppressor genes such as CDKN2A, BRCA2,
TP53 and SMAD4, with the latter three mutations occurring in
advanced-stage disease. Epigenetic dysregulation is also impli-
cated in the pathogenesis of pancreatic cancer and in neoplasms
without genetic inactivation of tumor suppressor genes, gene
silencing can occur via promoter methylation [9]. Currently, a
demethylation agent, azacitidine, is being assessed in combination
with gemcitabine in a phase I clinical trial in 30 patients with
advanced disease (NCT01167816) and trial completion is sched-
uled for July 2014.
It is also becoming clear that pancreatic cancer tumors are
highly heterogeneous, with results from a global landmark geno-
mic analysis of 24 advanced pancreatic adenocarcinomas showing
that tumors contain on average 63 genetic alterations. This heter-
ogeneity may partially explain the notorious resistance of pancre-
atic cancer to chemotherapy and, unfortunately, it may also render
the idea of targeted therapies to speciﬁc tumor mutations as lar-
gely unrealistic [21].The pancreatic cancer microenvironment
Epithelial-mesenchymal transition
Characterized by multiple biochemical changes resulting in loss
of cell polarity and transformation of an epithelial cell into a mes-
enchymal cell phenotype, the epithelial-mesenchymal transition
(EMT) is a pivotal process in tumor progression. EMT enables can-
cer cells to become unanchored from the primary tumor and to
subsequently disseminate into the bloodstream [22], thus initiat-
ing the ﬁrst steps in the establishment of micrometastases and
the ability of pancreatic cancer to undergo this process at a partic-
ularly early stage in disease development is one of the major rea-
sons for its dismal prognosis [23]. Tumor growth factor-beta
(TGF-ß) is one of the key induction agents of EMT [24], as well as
being a mediator of ﬁbrosis within the stroma. Recently, trabeder-
sen, an inhibitor of TGF-ß receptor-2, demonstrated activity in a
phase I trial in patients with advanced TGF-ß overexpressing solid
tumors, with a median overall survival duration of 9.2 months
being observed in the subgroup of patients with pancreatic
cancer [25].
As well as contributing to disease progression, EMT also plays
a role in the development of drug resistance. In a recent study
which aimed to characterize the resistance of pancreatic cancer
cell lines to 3 different classes of cytotoxic chemotherapy (gem-
citabine, 5-FU and cisplatin), high levels of transcriptional factor
Zeb-1, an EMT activator, and low levels of E-cadherin, a cell adhe-
sion protein, were associated with increased resistance to all 3
drugs; subsequent silencing of Zeb1 increased E-cadherin levels
and restored drug sensitivity [26]. Similar results have been
observed with targeted biologics as well [27]. Inhibition of
Notch-2 has been found to downregulate Zeb1 expression and
recently a clinical trial was conducted that assessed the prelimin-
ary efﬁcacy and pharmacodynamic effects of a notch signaling
pathway inhibitor, RO4929097 (RG-4733), in patients with meta-
static disease (NCT01232829). However, results from this trial
have yet to be published.
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As a result of genomic instability and inappropriate gene
expression, tumor cells express antigens that differentiate them
from normal cells and thus provide potential targets for recogni-
tion by the immune system. However, although many types of
immune cells are associated with tumor suppression, such as
tumor-inﬁltrating lymphocytes, tumor-promoting roles have been
identiﬁed in cells such as myeloid-derived suppressor cells, tumor-
associated macrophages and B-cells [28]. Due to the tumor micro-
environment being chronically inﬂamed, immunosuppressive cells,
such as macrophages and regulatory T-cells, are recruited to the
stroma, resulting in a decrease in antitumor immunity which is
more pronounced in pancreatic cancer, compared with other solid
tumors [29].
CD40, a tumor necrosis factor-receptor super family member,
has emerged as an attractive therapeutic target due to its central
role in mediating antitumor immunity [30]. In the ﬁrst part of a
study conducted in 2011, treatment-naïve patients with advanced
unresectable pancreatic cancer were treated with a fully human
agonist CD40 monoclonal antibody, CP-870, 893 as well as gemcit-
abine. Of the 21 patients, 19% had a partial response, 52% had sta-
ble disease and treatment was well tolerated. Similar results were
subsequently demonstrated with administration of CD40 agonist
FGK45 plus gemcitabine in a murine model which replicated the
tumor stroma (KrasLSL-G12D/+;Trp53LSL-R172H/+;Cre [KPC] mice), with
tumor regression being observed in 30% of mice. Interestingly,
the activity of FGK45 in KPC mice did not appear to be dependent
on the presence of T-cells or gemcitabine but did require macro-
phages, with CD40-activated macrophages being shown to rapidly
inﬁltrate tumors where they transformed into tumoricidal cells,
facilitating depletion of the tumor stroma [29].
The pancreatic cancer stroma
Overview
Formed as a result of a desmoplastic reaction, the stroma has
recently emerged as a key mediator of pancreatic cancer growth
and invasion as well as being a major factor in the notable resis-
tance pancreatic cancer to chemotherapy. This is in contrast to ear-
lier views of the stroma functioning merely as a mechanical
protective barrier for the beneﬁt of the host [31]. It is now recog-
nized that the stroma functions as a dynamic interface between
the tumor and normal host epithelial tissue and comprises com-
pact ﬁbrous tissue as well as cells such as pancreatic stellate
cells/cancer-associated stromal ﬁbroblasts, endothelial cells,
immune cells and tumor cells as well as extracellular matrix
(ECM) proteins and growth factors [32]. Moreover, compared with
other solid tumors, the pancreatic cancer stroma is particularly
dense and abundant, comprising up to 90% of tumor volume
[31]. Consequently, it has been one of the major obstacles in drug
development for pancreatic cancer due to the difﬁculty in replicat-
ing it in preclinical models and, as a result, drugs that initially
appear promising often fail in subsequent clinical trials. However,
it is now becoming clear that in order to elicit a meaningful
response and improve patient survival, treating the primary tumor
in pancreatic cancer is not enough – the tumor stroma must be tar-
geted as well.
Pancreatic stellate cells/cancer-associated stromal ﬁbroblasts
Pancreatic stellate cells are considered to be the principal regu-
lators of stromal formation and turnover. Upon activation from
their usual quiescent state by various cytokines and growth factors
as well as oxidative stress, they transform into myoﬁbroblast-likecells, secreting large amounts of ECM proteins and growth factors,
resulting in increased proliferation of tumor cells. Moreover, the
accumulation of ECM proteins into periacinar spaces as well as
the unchecked increase in levels of pancreatic stellate cells distorts
the normal parenchymal structure of the tumor. This results in
increased interstitial pressure, subsequent capillary compression
and impaired blood perfusion which hinders delivery of chemo-
therapy as well as oxygen diffusion. This induced hypoxic state
also promotes tumor cell survival, progression, invasion and
metastasis via activation of a range of genes by hypoxia-inducible
factor 1-a and induces EMT [33], contributing further to chemore-
sistance. Due to playing such a central role in stroma development,
tumor progression and chemoresistance, pancreatic stellate cells
are therefore considered to be an attractive therapeutic target.
Platelet-derived growth factor (PDGF) is a powerful chemoat-
tractant for pancreatic stellate cells [34] and also functions as a
promoter of pancreatic stellate cell proliferation. It was hypothe-
sized that inhibition of PDGF signaling could decrease levels of
pancreatic stellate cells, leading to reduced intratumoral intersti-
tial pressure and, consequently, increased uptake of chemotherapy.
This hypothesis was conﬁrmed in preclinical trials, including one
in which co-administration of imatinib, a PDGF receptor inhibitor,
with gemcitabine resulted in a tumor sized 36% smaller than the
tumor treated with gemcitabine alone [35]. Unfortunately, a
recently completed phase II study showed no difference in progres-
sion-free survival or overall survival between the imatinib plus
gemcitabine and gemcitabine alone arms [36].
Hyaluronic acid
Another component of the stroma which is present in high lev-
els is hyaluronic acid. Within the stroma, hyaluronic acid levels are
a major determinant of elevated interstitial ﬂuid pressures and
administration of hyaluronidase in KPC mice resulted in normali-
zation of interstitial ﬂuid pressure and, consequently, a signiﬁcant
increase in the diameters of CD31 + vessels. A subsequent preclin-
ical trial in KPC mice compared gemcitabine plus hyaluronidase vs.
gemcitabine alone. Of the evaluable tumors, 83% of gemcitabine
plus hyaluronidase-treated tumors had an objective clinical
response whereas no responses were observed in the gemcitabine
plus placebo-treated tumors [37]. Unfortunately, this success was
not replicated in a subsequent phase I/II clinical trial [38]. In a ran-
domized open-label phase II trial, gemcitabine plus nab-paclitaxel
plus hyaluronidase is being compared with gemcitabine plus nab-
paclitaxel alone (NCT01839487). The primary endpoint is progres-
sion-free survival and completion is scheduled for September
2015.
Sonic hedgehog pathway
Recently it was observed that cancer-associated stromal ﬁbro-
blasts overexpress the Hedgehog receptor smoothened (SMO),
leading to inappropriate activation and deregulation of the Sonic
Hedgehog (SHH) pathway, a key signaling pathway in embryogen-
esis and a prominent characteristic of pancreatic cancer [39]. As a
result of these ﬁndings, inhibition of the SMO receptor was inves-
tigated in several preclinical studies. In one study, administration
of gemcitabine with the SMO receptor inhibitor saridegib in gem-
citabine-resistant KPC mice resulted in increased tumor vascula-
ture, a higher intratumoral gemcitabine concentration and
extended overall survival [40]. Similar ﬁndings were observed in
other preclinical studies. However, although these data provided
a strong rationale for investigating inhibition of the SHH pathway
in a clinical setting, results so far have been disappointing [41,42].
Once again, translation of preclinical results into meaningful clini-
cal improvements in pancreatic cancer patients proved more difﬁ-
cult than expected.
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As well as the SMO receptor, cancer-associated stromal ﬁbro-
blasts also overexpress the SPARC protein. SPARC is also found in
approximately 80% of pancreatic adenocarcinomas [30] but the
promoter is often silenced in tumor cells via hypermethylation
[43]. However, SPARC in the stroma is active and high levels are
associated with a poor prognosis [44]. SPARC belongs to the matri-
cellular class of proteins and functions predominantly as a regula-
tor of tissue remodeling, including inﬂuencing the deposition and
composition of the ECM. Additionally, SPARC decreases the activa-
tion threshold of speciﬁc growth factors by increasing complex for-
mation of growth factors and enhancing cross-talk between
integrins and growth factor receptors. Therefore, it would appear
that SPARC plays a key role in the tumor-ECM interface and, conse-
quently in tumor proliferation, invasion, metastasis and survival
[43].
One of the ﬁrst observations leading to identiﬁcation of this
protein was its binding afﬁnity to albumin. SPARC mediates accu-
mulation of albumin in the tumor which is then thought to be used
for nutrition as well as a nitrogen source to synthesize new pro-
teins. It is hypothesized that nab-paclitaxel, which comprises albu-
min-bound paclitaxel, takes advantage of this particular action of
SPARC as well as other albumin-dependent processes [45]. How-
ever, data to conﬁrm this hypothesis are still pending. In a preclin-
ical component of a recent phase II study, co-administration of
nab-paclitaxel plus gemcitabine in 11 patient-derived pancreatic
cancer xenografts resulted in a higher tumor regression rate than
either agent alone with aggregate regression rates of 55%, 36%
and 24% in murine models of pancreatic cancer receiving nab-pac-
litaxel plus gemcitabine, nab-paclitaxel alone and gemcitabine
alone, respectively (Fig. 1). Additionally, greater stromal depletion
and vascularity were observed with the combination, compared to
either monotherapy, and the intratumoural gemcitabine concen-
tration was 2.8 times higher than that observed with gemcitabine
alone. In the clinical part of the trial, co-administration of the max-
imum tolerated dose of gemcitabine with nab-paclitaxel in
patients with advanced pancreatic cancer resulted in an objective
response rate of 48%, a median overall survival duration of
12.2 months and a 1-year survival rate of 48% [46]. These promis-Fig. 1. Percentage incidence of aggregate tumor regression in response to gemcit-
abine, nab-paclitaxel and gemcitabine plus nab-paclitaxel in mice xenografts [46].ing clinical results were recently validated in the pivotal phase III
MPACT clinical trial [47,48], thus making nab-paclitaxel the ﬁrst
drug hypothesized to target the stroma to reach this milestone
so far.
Another proposed mechanism for the increased accumulation
of nab-paclitaxel, compared with standard paclitaxel, is its
enhanced transport across endothelial cells. This is thought to
occur via binding of the albumin-paclitaxel complex to the gp60
albumin receptor on the surface of endothelial cells following drug
dissolution, leading to caveolae formation and subsequent caveo-
lin-1 mediated transcytosis of the vesicles through the endothelial
cell where they are subsequently emptied into the subendothelial
space. Once inside the subendothelial space, nab-paclitaxel seems
to bind to various extracellular matrix proteins, including SPARC,
and is then taken up by the tumor [49].
Nab-paclitaxel vs. standard paclitaxel
In addition to its possible afﬁnity to SPARC, the high intratumo-
ural concentration of nab-paclitaxel is thought to be due to phar-
macokinetics, with nab-paclitaxel demonstrating a peak drug
concentration of free paclitaxel that is approximately 10 times
higher than that of standard paclitaxel (1283.7 vs. 121.79 ng/mL;
p < 0.000001), and an AUC that is approximately 3 times higher
(1159 vs. 410 h*ng/mL; p < 0.000005) when both drugs are admin-
istered at approved doses. Moreover, nab-paclitaxel also demon-
strates dose exposure/linearity over a clinically relevant dose
range whereas, due to micellar encapsulation by the solvent poly-
oxyl-35 castor oil, standard paclitaxel demonstrates limited drug
distribution and clearance and, consequently, nonlinear pharmaco-
kinetics [50]. Another beneﬁt of not requiring polyoxyl-35 castor
oil for dissolution is improved tolerability, compared with standard
paclitaxel [51].
Pancreatic mast cells
Mast cells promote proliferation of pancreatic stellate cells
within the desmoplastic environment via production of interleu-
kin-13 and tryptase, thus rendering them a promising target for
the inhibition of stromal formation [52]. In a phase III trial,
chemo-naïve pancreatic cancer patients (n = 348) received the
selective mast/stem cell growth factor receptor (c-Kit) inhibitor
masitinib [53], in combination with gemcitabine. A signiﬁcant sur-
vival advantage over gemcitabine monotherapy was observed in
the subgroups of patients with ‘‘pain’’ (8.1 vs. 5.4 months) and
the prognostic biomarker GBM (11.0 vs. 5.0 months), but not in
the overall patient population [53].
Inhibition of Janus kinases
The STAT protein (Signal Transducer and Activator of Transcrip-
tion) is responsible for many major cell functions, such as growth,
survival and differentiation, and is activated by Janus kinase (JAK)
[54]. Activation of the JAK/STAT pathway plays a role in many con-
ditions such as inﬂammatory diseases and cancer. Ruxolitinib is an
oral JAK1 and JAK2 inhibitor that has recently been approved for
the treatment of myeloﬁbrosis and has also been tested against dif-
ferent solid tumours, including pancreatic cancer [54]. Results
from a phase II study of ruxolitinib in combination with capecita-
bine resulted in a hazard ratio for overall survival of 0.47 in a sub-
group of pancreatic cancer patients with C-reactive protein levels
that were higher than the treatment armmedian of 13 mg/L. In this
same subgroup, the 3- and 6-month survival rates were 48% and
42%, compared to 29% and 11% in the capecitabine monotherapy
group, respectively [55].
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Gemcitabine vs. ﬂuorouracil
Gemcitabine monotherapy has been the standard of care for
advanced pancreatic cancer since 1997 when a pivotal study by
Burris et al., demonstrated superiority of gemcitabine over 5-FU
(Tables 1–4). The primary endpoint of this study was clinical ben-
eﬁt response, a composite of pain intensity, analgesic consumption,
bodyweight and Karnofsky performance status, with survival being
a secondary outcome. As compared to 5-FU, gemcitabine resulted
in a signiﬁcantly higher proportion of patients experiencing a clin-
ical beneﬁt response (23.8% vs. 4.8%; p = 0.0022), as well as a signif-
icantly higher 1-year survival rate (18% vs. 2% of patients) and a
signiﬁcantly longer survival duration (median of 5.65 vs.
4.41 months; p = 0.0025). Both treatments were generally well tol-
erated with rates of hematological and non-hematological adverse
events being low and usually of a mild severity. However, gemcit-
abine was associated with non-signiﬁcantly higher rates of grade 3
or 4 nausea/vomiting and anemia (12.7% vs. 4.8% and 9.7% vs. 0% of
patients, respectively) and a signiﬁcantly higher rate of grade 3 or 4
neutropenia (25.9% vs. 4.9% of patients; p < 0.001) [14].
Erlotinib plus gemcitabine vs. gemcitabine alone: the PA.3 trial
Targeted therapies have generally proven disappointing in clin-
ical trials of patients with pancreatic cancer, despite demonstrating
efﬁcacy in other solid malignancies. The only phase III trial to show
a signiﬁcant improvement in survival was the multinational PA.3
trial, comparing erlotinib plus gemcitabine with gemcitabine alone
(Tables 1–4). The increase in survival in the erlotinib plus gemcit-
abine arm was signiﬁcant but modest (median of 6.24 vs.
5.91 months; hazard ratio 0.82, 95% CI 0.69, 0.99). Erlotinib plus
gemcitabine was associated with higher rates of diarrhea, rash, sto-
matitis and infection although most of these were only grade 1 or 2
in severity. As previously observed in other studies, appearance of
a rash was signiﬁcantly correlated with improved disease control
(p = 0.05) as well as survival, with erlotinib recipients experiencing
a grade 2 or higher rash living signiﬁcantly longer than those
patients with no rash or a grade 1 rash (median of 10.5 vs. 5.3
and 5.8 months, respectively; p < 0.001). However, only 36% of erl-
otinib plus gemcitabine recipients developed a rash of grade 2 or
higher and overall survival in the majority of erlotinib plus gemcit-
abine recipients was similar to gemcitabine alone [56]. Therefore,
due to the increase in survival being so small in the general patient
population, erlotinib has not been broadly adopted by oncologists
as part of standard of care.
FOLFIRINOX vs. gemcitabine: the ACCORD-4 trial
A multicenter phase III trial in France was completed in 2010 in
which a median survival duration of 11.1 months was achieved forTable 1
Pivotal phase III trials in patients with advanced disease. Bold values symbolize the treatm
Number of
patients
Treatment
[14] 126 Gemcitabine (1000 mg/m2 weekly  7, 1 week arrest, then
[56] 569 Gemcitabine (standard) + erlotinib (100 or 150 mg/d orally
[57] 342 FOLFIRINOX (oxaliplatin, 85 mg/m2; irinotecan, 180 mg/m2;
m2 46-h continuous infusion every 2 weeks) vs. gemcitabin
[48] 861 NABPAC (125 mg/m2 followed by gemcitabine 1000 mg/m2
8 weeks and on days 1, 8, and 15 every 4 weeks)the ﬁrst time in patients with metastatic pancreatic cancer. The
treatment regimen administered was FOLFIRINOX with the com-
parator arm (gemcitabine monotherapy) resulting in a signiﬁcantly
shorter median survival duration (6.8 months; primary endpoint)
(Tables 1–4). FOLFIRINOX was also associated with a signiﬁcantly
longer progression-free survival interval (median of 6.4 vs.
3.3 months; p < 0.001) and a signiﬁcantly higher objective clinical
response rate (31.6% vs. 9.4% in the intention-to-treat population;
p < 0.001). Furthermore, time to deﬁnitive deterioration in quality
of life, with respect to function and symptom scale scores as well
as constipation, dyspnea and loss of appetite, was signiﬁcantly pro-
longed in the FOLFIRINOX arm, compared with gemcitabine alone.
Unfortunately, the greater efﬁcacy of FOLFIRINOX was accompa-
nied by a substantial increase in toxicity; in particular grade 3/4
diarrhea, sensory neuropathy, neutropenia and febrile neutropenia
(p < 0.001, p < 0.001, p < 0.001 and p < 0.05, respectively, vs. gem-
citabine alone) [57]. The study also contained strict inclusion crite-
ria-patients had to be younger than 76 years of age, have an ECOG
performance status of no more than 1 as well as no cardiac ische-
mia. Moreover, due to an increased risk of irinotecan-associated
toxicity, only patients with good hepatobiliary function were
enrolled and, as a result, the distribution of pancreatic tumor loca-
tion was the opposite to what would normally be seen in clinical
practice, with approximately 60% of patients having non-head
tumors of the pancreas and, consequently, only 14% of patients
had an endobiliary stent [58]. In normal clinical practice, a ratio
of 3:1 for head lesions vs. body or tail lesions is usually observed
[59]. As the risk of ascending cholangitis and biliary sepsis is higher
in patients with obstructing pancreatic head lesions and indwell-
ing biliary stents, the increased likelihood of grade 3/4 neutropenia
associated with the FOLFIRINOX regimen could result in poten-
tially life-threatening situations. This would be especially serious
in centers with limited or no access to specialists in endoscopic
management of biliary complications [58]. However, it is not cer-
tain whether all components of FOLFIRINOX are necessary and
modiﬁed regimens are currently being evaluated. A retrospective
study investigated a modiﬁed FOLFIRINOX regimen in which the
ﬂuorouracil bolus was omitted and prophylactic growth factor
was added. Results were promising, with the modiﬁed regimen
appearing to be well tolerated, although it needs to be validated
in a prospectively planned clinical trial [60].
Therefore, although FOLFIRINOX is an effective regimen, thus
far it is unsuitable for many patients due to its toxicity and as a
result its clinical impact is thought to be modest.Nab-paclitaxel + gemcitabine vs. gemcitabine alone: the MPACT trial
In November 2012, the primary endpoint was met in the pivotal
phase III multinational MPACT trial, with nab-paclitaxel plus gem-
citabine demonstrating signiﬁcantly longer overall survival than
gemcitabine alone (median duration of 8.7 vs. 6.6 months; hazard
ratio 0.72; 95% CI 0.620, 0.825; updated cutoff May 9th 2013) in
patients with metastatic pancreatic cancer (Tables 1–4). Thisent of interest.
weekly  3 every 4 weeks) vs. 5-FU (600 mg/m2 once weekly)
) vs. Gemcitabine + placebo
leucovorin, 400 mg/m2; and ﬂuorouracil, 400 mg/m2 bolus followed by 2400 mg/
e (1000 mg/m2 weekly for 7 of 8 weeks, then weekly for 3 of 4 weeks)
on days 1, 8, and 15 every 4 weeks) vs. gemcitabine (1000 mg/m2 weekly for 7 of
Table 2
Patient demographics in pivotal phase III trials in patients with advanced disease.
[14] [56] [57] [48]
GEM GEM/ERL FOLFIRINOX NABPAC
Age (range) 62 (37–79) 63.7 (37–84) 61 (25–76) 62 (27–88)
Performance status 30% KPS 80–90 29.8% ECOG 0 37.4% ECOG 0 16% KPS 100
70% KPS 50–70 50.9% ECOG 1 61.9% ECOG 1 77% KPS 80–90
18.9% ECOG 2 0.6% ECOG 2 7% KPS 60–70
Liver metastases NR NR 87.6% 85%
Head of pancreas NR NR 39.2% 44%
CA19.9P 59 ULN NR NR 41.5% 52%
GEM, gemcitabine; ERL, erlotinib; FOLFIRINOX, folinic acid + ﬂuorouracil + irinotecan + oxaliplatin; NABPAC, nab-paclitaxel; KPS, Karnofsky performance status; ECOG,
Eastern Cooperative Oncology Group performance status; ULN, upper limit of normal; NR, not reported.
Table 3
Clinical outcomes in pivotal phase III trials in patients with advanced disease.
[14] [56] [57] [48]
GEM GEM/ERL FOLFIRINOX NABPAC
OS (median months) 5.65 6.24 11.1 8.7
p = 0.0025 p = 0.038 p = 0.001 p < 0.001
12-month OS (% patients) 18 23 48.4 35
18-month OS (% patients) NR NR 18.6 16
ORR (% patients) 5.4 8.6 31.6 29.2
ORR, overall response rate; OS, overall survival; GEM, gemcitabine; ERL, erlotinib; FOLFIRINOX, folinic acid + ﬂuorouracil + irinotecan + oxaliplatin; NABPAC, nab-paclitaxel.
Table 4
Grade 3 or higher adverse events (% patients) in pivotal phase III trials.
[14] [56] [57] [48]
GEM GEM/ERL FOLFIRINOX GEM/NABPAC
Neutropenia 25.9 24 45.7 38
Febrile neutropenia NR NR 5.4 3
Thrombocytopenia 9.7 10 9.1 13
Fatigue NR 15 23.6 17
Diarrhea 1.6 6 12.7 6
Peripheral neuropathy NR NR 9.0 17a
GEM, gemcitabine; ERL, erlotinib; FOLFIRINOX, folinic acid + ﬂuorouracil + irinotecan + oxaliplatin; NABPAC, nab-paclitaxel; NR, not reported.
a GradeP 3 neuropathy improved to no more than grade 1 in a median of 29 days.
1044 H. Oettle / Cancer Treatment Reviews 40 (2014) 1039–1047improvement in overall survival was observed across almost all
patient subgroups, with the patients who had more advanced dis-
ease deriving the greatest beneﬁt from the nab-paclitaxel plus
gemcitabine combination. In particular, patients with more than
3 metastatic sites, a Karnofsky performance status of 70–80, pres-
ence of liver metastases or a CA19-9 level which was 59 times the
upper limit of normal or higher had the greatest reduction in the
risk of death.
Other signiﬁcantly improved endpoints included progression-
free survival (median interval of 5.5 vs. 3.7 months; p < 0.001)
and objective response (complete plus partial response) (29% vs.
8% in the intention-to-treat population; p < 0.001). Moreover, the
1-year survival rate was signiﬁcantly higher in the nab-paclitaxel
arm plus gemcitabine, compared with gemcitabine alone (35% vs.
22% in the intention-to-treat population; p < 0.001), as was the 2-
year survival rate in the intention-to-treat population. The
response rate according to independent review was 23% in the
nab-paclitaxel group versus 7% in the comparator arm
(p < 0.001). With respect to tolerability, nab-paclitaxel plus gemcit-
abine was associated with increased but manageable toxicity, with
the most frequently reported grade 3 or higher adverse events
being neutropenia (38% vs. 27% of patients), leukopenia (31% vs.
16% of patients), fatigue (17% vs. 7% of patients) and neuropathy(17% vs. 1% of patients). However, median times to decrease from
grade 3 to either grade 2 neuropathy or neuropathy of grade 1 or
lower were relatively short (21 and 29 days, respectively) [47,48].
Therefore, due to resulting in a substantially longer overall sur-
vival duration, compared with standard of care, as well as being
associated with a manageable increase in toxicity, nab-paclitaxel
plus gemcitabine can be considered to be an important new regi-
men in the treatment of advanced pancreatic cancer.
Is nab-paclitaxel + gemcitabine a new treatment standard?
Although inter-study comparisons of pivotal trials are inher-
ently limited, they can nevertheless provide a useful overview of
current treatment landscapes. Nab-paclitaxel plus gemcitabine
resulted in a substantially longer median overall survival duration
than the gemcitabine monotherapy arm in the 1997 study by Bur-
ris et al., as well as the erlotinib plus gemcitabine arm in the PA.3
trial (8.5 vs. 5.65 vs. 6.24 months, respectively) and was associated
with less toxicity than the FOLFIRINOX regimen, particularly with
respect to neutropenia. Furthermore, the MPACT trial differed from
the FOLFIRINOX trial in several important aspects, including allow-
ing patients to enroll with an ECOG performance status of 2 as well
as enrolling patients 75 years or older. In fact, 10% of the patient
Fig. 2. Treatment algorithm for advanced metastatic pancreatic cancer.
H. Oettle / Cancer Treatment Reviews 40 (2014) 1039–1047 1045population in the MPACT trial were at least 75 years of age and 8%
had a KPS of 60–70%, equivalent to an ECOG of 2 [48].
As a result of the positive data from the MPACT trial, the
National Cancer Association Network updated its guidelines for
the treatment of pancreatic cancer in April 2013, with nab-paclit-
axel plus gemcitabine being moved from a category 2B to a cate-
gory 1 listing, deﬁned as being ‘‘based on high-level evidence,
there is uniform NCCN consensus that the intervention is appropri-
ate’’ [61].
Additionally, following a Priority Review granted by the FDA in
May 2013 [62], nab-paclitaxel received approval in September
2013 to be administered in combination with gemcitabine as
ﬁrst-line therapy for metastatic pancreatic cancer [63], thus mak-
ing it the ﬁrst drug to be approved for advanced pancreatic cancer
in nearly 8 years. Furthermore, EMA approval was granted in
December 2013. Nab-paclitaxel plus gemcitabine should therefore
be considered as an eminent therapeutic option in patients with
advanced pancreatic cancer, administered either alone or as a
backbone in other treatment regimens.
Conclusion
Although progress has been made in the treatment of advanced
pancreatic cancer in the last 15 years, it is clear that new strategies
are needed if patients’ lives are to be substantially prolonged and it
is becoming clear that targeting the primary tumor alone is inade-
quate in this most resilient of malignancies. The relatively recent
discovery that the tumor microenvironment is a key player in
tumor progression and metastasis as well as immune evasion
and moreover, that the stroma is a major factor in the notable drug
resistance of pancreatic cancer, has initiated somewhat of a para-
digm shift in the way pancreatic cancer and its treatment are
viewed. Novel regimens in which a multi-faceted approach is
undertaken, targeting not only the primary tumor, but also the sur-
rounding structures such as the tumor stroma, are starting to be
investigated, with the hope of increasing response rates and, con-
sequently, survival. Many early-phase studies of these multitarget-
ed regimens are now active and their results are eagerly awaited
by the oncology community.
Nab-paclitaxel plus gemcitabine is the ﬁrst of such regimens to
be validated in a phase III setting in patients with metastatic pan-
creatic cancer. This combination demonstrated a signiﬁcantly
greater improvement in the hard endpoint of overall survival whencompared with the reference regimen of gemcitabine alone and as
a result it joins the growing armamentarium against this challeng-
ing disease. A treatment algorithm for patients with advanced met-
astatic pancreatic cancer is given in Fig. 2. As our understanding of
pancreatic cancer biology grows, so too does the likelihood of being
able to implement therapeutic regimens in real-life settings that
result in meaningful improvements in survival and quality-of-life
outcomes accompanied by acceptable tolerability. Hopefully, the
recent success observed with nab-paclitaxel marks the beginning
of a new era in the treatment of advanced metastatic pancreatic
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